Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
21 01 2021
Historique:
received: 06 04 2020
accepted: 03 07 2020
pubmed: 22 7 2020
medline: 13 5 2021
entrez: 22 7 2020
Statut: ppublish

Résumé

There is growing evidence supporting an inherited basis for susceptibility to acute lymphoblastic leukemia (ALL) in children. In particular, we and others reported recurrent germline ETV6 variants linked to ALL risk, which collectively represent a novel leukemia predisposition syndrome. To understand the influence of ETV6 variation on ALL pathogenesis, we comprehensively characterized a cohort of 32 childhood leukemia cases arising from this rare syndrome. Of 34 nonsynonymous germline ETV6 variants in ALL, we identified 22 variants with impaired transcription repressor activity, loss of DNA binding, and altered nuclear localization. Missense variants retained dimerization with wild-type ETV6 with potentially dominant-negative effects. Whole-transcriptome and whole-genome sequencing of this cohort of leukemia cases revealed a profound influence of germline ETV6 variants on leukemia transcriptional landscape, with distinct ALL subsets invoking unique patterns of somatic cooperating mutations. 70% of ALL cases with damaging germline ETV6 variants exhibited hyperdiploid karyotype with characteristic recurrent mutations in NRAS, KRAS, and PTPN11. In contrast, the remaining 30% cases had a diploid leukemia genome and an exceedingly high frequency of somatic copy-number loss of PAX5 and ETV6, with a gene expression pattern that strikingly mirrored that of ALL with somatic ETV6-RUNX1 fusion. Two ETV6 germline variants gave rise to both acute myeloid leukemia and ALL, with lineage-specific genetic lesions in the leukemia genomes. ETV6 variants compromise its tumor suppressor activity in vitro with specific molecular targets identified by assay for transposase-accessible chromatin sequencing profiling. ETV6-mediated ALL predisposition exemplifies the intricate interactions between inherited and acquired genomic variations in leukemia pathogenesis.

Identifiants

pubmed: 32693409
pii: S0006-4971(21)00090-2
doi: 10.1182/blood.2020006164
pmc: PMC7819760
doi:

Substances chimiques

Proto-Oncogene Proteins c-ets 0
Repressor Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

364-373

Subventions

Organisme : NHLBI NIH HHS
ID : F31 HL154645
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA241452
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021 by The American Society of Hematology.

Auteurs

Rina Nishii (R)

Department of Pharmaceutical Sciences and.

Rebekah Baskin-Doerfler (R)

Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN.

Wentao Yang (W)

Department of Pharmaceutical Sciences and.

Ninad Oak (N)

Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN.

Xujie Zhao (X)

Department of Pharmaceutical Sciences and.

Wenjian Yang (W)

Department of Pharmaceutical Sciences and.

Keito Hoshitsuki (K)

Department of Pharmaceutical Sciences and.

Mackenzie Bloom (M)

Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN.

Katherine Verbist (K)

Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN.

Melissa Burns (M)

Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

Zhenhua Li (Z)

Department of Paediatrics, National University of Singapore, Singapore, Singapore.

Ting-Nien Lin (TN)

Department of Pharmaceutical Sciences and.

Maoxiang Qian (M)

Department of Pharmaceutical Sciences and.
Children's Hospital of Fudan University, Shanghai, China.
Institutes of Biomedical Sciences, Fudan University, Shanghai, China.

Takaya Moriyama (T)

Department of Pharmaceutical Sciences and.

Julie M Gastier-Foster (JM)

Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH.
Department of Pathology and.
Department of Pediatrics, The Ohio State University, Columbus, OH.

Karen R Rabin (KR)

Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX.

Elizabeth Raetz (E)

Department of Pediatrics, NYU Langone Medical Center, New York, NY.

Charles Mullighan (C)

Department of Pathology and.
Hematological Malignancies Program, Comprehensive Cancer Center, St. Jude Children's Research Hospital, Memphis, TN.

Ching-Hon Pui (CH)

Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN.
Hematological Malignancies Program, Comprehensive Cancer Center, St. Jude Children's Research Hospital, Memphis, TN.

Allen Eng-Juh Yeoh (AE)

Khoo Teck Puat-National University Children's Medical Institute, National University Hospital, National University Health System, Singapore, Singapore.
VIVA-NUS Center for Translational Research in Acute Leukaemia, Department of Paediatrics, Yong Loo Lin School of Medicine, Singapore, Singapore.
Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.

Jinghui Zhang (J)

Department of Computational Biology and.

Monika L Metzger (ML)

Hematological Malignancies Program, Comprehensive Cancer Center, St. Jude Children's Research Hospital, Memphis, TN.
Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN.

Jeffery M Klco (JM)

Department of Pathology and.
Hematological Malignancies Program, Comprehensive Cancer Center, St. Jude Children's Research Hospital, Memphis, TN.

Stephen P Hunger (SP)

Department of Pediatrics and Center for Childhood Cancer Research, Children's Hospital of Philadelphia and the Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA.

Scott Newman (S)

Department of Computational Biology and.

Gang Wu (G)

Department of Computational Biology and.

Mignon L Loh (ML)

Department of Pediatrics, Benioff Children's Hospital, San Francisco, CA; and.
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.

Kim E Nichols (KE)

Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN.
Hematological Malignancies Program, Comprehensive Cancer Center, St. Jude Children's Research Hospital, Memphis, TN.

Jun J Yang (JJ)

Department of Pharmaceutical Sciences and.
Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN.
Hematological Malignancies Program, Comprehensive Cancer Center, St. Jude Children's Research Hospital, Memphis, TN.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH